Similar articles for PMID: 23687347

Year	Number of Results
2007	1
2009	1
2010	4
2011	6
2012	19
2013	9
2014	11
2015	24
2016	16
2017	25
2018	22
2019	17
2020	19
2021	13
2022	14
2023	3
2024	0

1

Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.

Muñoz-Pinedo C, González-Suárez E, Portela A, Gentilella A, Esteller M. Muñoz-Pinedo C, et al. Cancer Res. 2013 Jul 15;73(14):4185-9. doi: 10.1158/0008-5472.CAN-13-0512. Epub 2013 May 17. Cancer Res. 2013. PMID: 23687347

2

New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.

Sun Z, Wang Z, Liu X, Wang D. Sun Z, et al. Anticancer Drugs. 2015 Jan;26(1):1-14. doi: 10.1097/CAD.0000000000000172. Anticancer Drugs. 2015. PMID: 25304988 Review.

3

Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine.

Lomberk G, Dusetti N, Iovanna J, Urrutia R. Lomberk G, et al. Nat Commun. 2019 Aug 28;10(1):3875. doi: 10.1038/s41467-019-11812-7. Nat Commun. 2019. PMID: 31462645 Free PMC article. Review.

4

Serine and one-carbon metabolism, a bridge that links mTOR signaling and DNA methylation in cancer.

Zeng JD, Wu WKK, Wang HY, Li XX. Zeng JD, et al. Pharmacol Res. 2019 Nov;149:104352. doi: 10.1016/j.phrs.2019.104352. Epub 2019 Jul 16. Pharmacol Res. 2019. PMID: 31323332 Free article. Review.

5

Epigenetics and Precision Oncology.

Werner RJ, Kelly AD, Issa JJ. Werner RJ, et al. Cancer J. 2017 Sep/Oct;23(5):262-269. doi: 10.1097/PPO.0000000000000281. Cancer J. 2017. PMID: 28926426 Free PMC article. Review.

6

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.

Polivka J Jr, Janku F. Polivka J Jr, et al. Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9. Pharmacol Ther. 2014. PMID: 24333502 Review.

7

Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer.

Kabekkodu SP, Chakrabarty S, Ghosh S, Brand A, Satyamoorthy K. Kabekkodu SP, et al. Public Health Genomics. 2017;20(2):100-115. doi: 10.1159/000475804. Epub 2017 May 19. Public Health Genomics. 2017. PMID: 28521327 Review.

8

Current treatment strategies for inhibiting mTOR in cancer.

Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Chiarini F, et al. Trends Pharmacol Sci. 2015 Feb;36(2):124-35. doi: 10.1016/j.tips.2014.11.004. Epub 2014 Dec 11. Trends Pharmacol Sci. 2015. PMID: 25497227 Review.

9

Pharmacoepigenetics: an element of personalized therapy?

Majchrzak-Celińska A, Baer-Dubowska W. Majchrzak-Celińska A, et al. Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):387-398. doi: 10.1080/17425255.2017.1260546. Epub 2016 Nov 28. Expert Opin Drug Metab Toxicol. 2017. PMID: 27860490 Review.

10

Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.

Lumachi F, Chiara GB, Foltran L, Basso SM. Lumachi F, et al. Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):385-90. Cancer Genomics Proteomics. 2015. PMID: 26543084 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

186 results

Results by year